Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of oral CF101 in moderate-to-severe plaque psoriasis
2010-024196-83Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing CF101 2 mg BID with Placebo (2 arms). Primary endpoints: Primary efficacy at 16 weeks and Primary safety over 32 weeks. Started Feb 2011; status: completed.
02
Drugs
piclidenoson
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2010-024196-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024196-83.